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Abstract: A transmural defect of the upper gastrointestinal (UGI) tract is a life-threatening condition
associated with high morbidity and mortality. Recently, endoscopic vacuum therapy (EVT) was used
for managing UGI defects and showed promising results. We conducted a systematic review and
meta-analysis to synthesize evidence on the efficacy of EVT in patients with transmural defects of the
UGI tract. We searched the PubMed, Cochrane Library, and Embase databases for publications on the
effect of EVT on successful closure, mortality, complications, and post-EVT strictures. Methodological
quality was assessed using the Newcastle–Ottawa quality assessment scale. This meta-analysis
included 29 studies involving 498 participants. The pooled estimate rate of successful closure with
EVT was 0.85 (95% confidence interval [CI]: 0.81–0.88). The pooled estimate rates for mortality,
complications, and post-EVT strictures were 0.11, 0.10, and 0.14, respectively. According to the
etiology of the transmural defect (perforation vs. leak and fistula), no significant difference was
observed in successful closure (odds ratio [OR]: 1.45, 95% CI: 0.45–4.67, p = 0.53), mortality (OR: 0.77,
95% CI: 0.24–2.46, p = 0.66), complications (OR: 0.94, 95% CI: 0.17–5.15, p = 0.94), or post-EVT stricture
rates (OR: 0.70, 95% CI: 0.12–4.24, p = 0.70). The successful closure rate was significantly higher with
EVT than with self-expanding metal stent (SEMS) placement (OR: 3.14, 95% CI: 1.23–7.98, p = 0.02).
EVT is an effective and safe treatment for leaks and fistulae, as well as for perforations in the UGI.
Moreover, EVT seems to be a better treatment option than SEMS placement for UGI defects.
Keywords: endoscopic vacuum therapy; etiology; transmural defect; upper gastrointestinal tract
1. Introduction
Transmural defects of the upper gastrointestinal (UGI) tract are categorized as perfora-
tions, leaks, or fistulae. A perforation is defined as an acute rupture of the gastrointestinal
wall that can occur after an endoscopic procedure or due to underlying pathology, such as
massive vomiting (Boerhaave syndrome), foreign bodies, peptic ulcers [1,2]. A leak is a
communication between the intraluminal and extraluminal spaces, which occurs because of
postsurgical complications, most commonly at the anastomosis site. A fistula that develops
owing to prolonged anastomotic leak is defined as an abnormal connection between the
gastrointestinal tract and other organs or abscess cavities. Tracheoesophageal fistula is
representative. Transmural defects of the UGI are life-threatening and associated with high
morbidity and mortality rates [3,4]. The optimal management of UGI transmural defects
remains controversial. Though surgery is an important treatment strategy, the associated
mortality rate is about 12–50% [3,5,6]. Placement of a self-expanding metal stent (SEMS)
was also proven to be an effective treatment strategy for UGI defects [7,8]. However,
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SEMS placement can also cause complications such as stent migration, stent ingrowth,
perforation, bleeding, epidural abscess, and vascular fistula [9–11].
Recently, endoscopic vacuum therapy (EVT) was used with promising results for
managing UGI defects [12–14]. This method involves the application of a continuous
negative pressure to drain the infected fluid and accelerates wound healing [15]. EVT is
suitable for localized defects for which stent placement is not feasible. Moreover, external
drainage is not necessary in most cases [16]; however, the clinical success rate of EVT varies
widely from 66.7–100% [17–19]. In addition, corroborating evidence is needed because most
studies are limited to case series and retrospective cohort studies with small sample sizes.
We performed a meta-analysis of studies on the clinical outcomes of EVT in patients
with transmural defects of the UGI tract. We aimed to assess the effect of EVT on successful
closure, mortality, postprocedural complications, and stricture. In addition, we evaluated
the efficacy of EVT according to the etiology of the transmural defect (perforation vs.
leak and fistula) and treatment method (EVT vs. SEMS placement).
2. Material and Methods
2.1. Literature Search Strategy
We performed a systematic review and meta-analysis following the principles of the
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) state-
ment [20]. The PubMed, Cochrane Library, and Embase databases (from inception to April
2020) were independently searched by three authors (DHJ, HRY, and CWH). We used
the following search string: anastomotic leak OR anastomotic leakage OR postoperative
leak OR postoperative leakage OR esophageal leak OR esophageal leakage OR esophageal
fistula OR leakage OR fistula OR leak OR perforation OR upper gastrointestinal tract OR
esophagus OR esophageal OR gastric OR stomach OR esophagectomy OR anastomosis
AND endoscopic vacuum therapy OR endoscopic vacuum-assisted closure OR endolu-
minal vacuum therapy OR vacuum therapy OR vacuum-assisted closure OR negative
pressure wound therapy OR endoscopic negative pressure therapy OR negative pressure
therapy OR endovac therapy OR endo sponge (as illustrated in supplementary Table S1).
We manually and repetitively searched the cited references in published studies to identify
other studies.
2.2. Study Selection
In the first stage of the study selection, the titles and abstracts of the articles that our
keyword search returned were scrutinised to rule out irrelevant articles. Thereafter, the full
texts of all selected studies were screened according to our inclusion and exclusion criteria.
The inclusion criteria were as follows: (1) a diagnosis of perforation, leak, or fistula of
the UGI tract; (2) EVT as a primary or rescue treatment; and (3) investigations of adults
aged ≥18 years. The exclusion criteria were as follows: (1) article types other than original
articles; (2) case reports including fewer than two patients; (3) abstract-only publications;
and (4) publications in a language other than English. Only the most recent study was
selected if several publications covering the same study population existed.
2.3. Data Extraction
Three authors (DHJ, HRY, and CWH) of this review independently extracted data
from the included studies using a predata extraction form. Further, we reviewed the
titles and abstracts of all the included studies to exclude irrelevant publications. Any dis-
crepancies in data interpretation were resolved through discussions, rereview of studies,
and consultation with another author (SJL). We extracted the following information: year
of publication, first author, study design, patient age and sex, sample size, study region,
follow-up duration, transmural defect size, time to diagnosis, time to treatment, EVT type,
successful closure rate, mortality rate, complication rate, post-EVT stricture rate, hospital
length of stay, intensive care unit length of stay, treatment duration, and number of sponge
or stent changes.
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2.4. Primary and Secondary Outcomes
The primary outcome was the successful closure rate. Successful closure was defined
as no evidence of leakage on direct endoscopic visualization and the absence of contrast
extravasation on either a computed tomography scan with oral contrast, esophagography,
or a UGI study. The secondary outcomes were mortality rate, complication rate (Clavien–
Dindo score ≥ 3), and stricture rate after EVT.
2.5. Methodological Quality
The Newcastle–Ottawa quality assessment scale for cohort studies was used to evalu-
ate the risk of bias. This scale rates studies on three sources of bias (selection, comparability,
and outcome) based on eight criteria. Each criterion is rated with 1 star except comparabil-
ity, which is rated a maximum of 2 stars. For this systematic review, the studies scoring
7–9 stars were defined be of low risk of bias, the studies scoring 4–6 stars were defined to
be of moderate risk of bias, and the studies scoring 1–3 stars were defined to be of high risk
of bias. Three authors (CWH, HRY, and DHJ) independently evaluated the methodological
quality of the selected studies. Any disagreement between the three authors was resolved
through discussions.
2.6. Statistical Analysis
A meta-analysis was performed using the statistical software R (version 3.3.3; R
Foundation for Statistical Computing, Vienna, Austria). The Mantel–Haenszel random-
effect model was applied to binary endpoints. The random-effects model was selected
because it considers the possibility of heterogeneity. The median difference was used
for continuous variables. Pooled medians were estimated using the quantile estimation
method. In addition, we performed subgroup analyses according to the following criteria:
closure rate, mortality rate, complication rate, post-EVT stricture rate according to the
etiology of transmural defect (perforation vs. leak and fistula), closure rate, mortality,
treatment duration, hospital stay, and number of sponge/stent changes of EVT and SEMS.
The I2 test developed by Higgins was used to determine heterogeneity [21]. This test
measures the percentage of total variation across studies. In cases of significant hetero-
geneity (I2 > 25%), the methodological section of each publication was re-evaluated to
determine whether any discrepancy could be checked. We used the Egger test to assess the
extent of the publication bias. Statistical significance was set at p < 0.05.
3. Results
3.1. Study Selection
A total of 2585 studies were identified. Duplicate articles (n = 392) were excluded.
Further, 2144 articles were rejected based on the title and abstracts. Forty-nine articles were
reviewed. After assessing eligibility, 20 articles were excluded (as illustrated in Figure 1).
Finally, a total of 29 articles were included involving 498 participants [13,14,18,22–47]





Figure 1. Flowchart of studies included in meta-analysis. 
3.2. Study Characteristics and Methodological Quality. 
The baseline characteristics of the included studies are presented in Table 1. Nineteen 
articles were retrospective cohort studies, and 10 were case series. Eight studies included 
only patients with postoperative leaks, [13,23,25,26,33,42,43,46] and two studies included 
only patients with perforations [24,27]. Eleven studies included patients with both post-
operative leaks and perforations [14,18,29,31,32,34,35,38,40,41,44]. Four studies included 
patients with a fistula [36,37,45,47]. Four studies compared EVT with SEMS placement 
[22,28,30,39]. A total of 24 studies were conducted in Western countries (Germany 14, 
United States 4, Switzerland 2, United Kingdom 2, Portugal 1, and Australia 1), whereas 
five studies were conducted in Asia (Korea 4 and China 1). 
Table 2 summarizes the clinical outcomes of the included studies. All studies except 
two [23,36] reported the successful closure rate. Mortality was reported in all studies ex-
cept one [40]. The complications and post-EVT stricture rates were reported in 21 and 16 
studies, respectively. Hospital stay, intensive care unit stay, duration of therapy, and the 
number of sponge changes were reported in 14, 5, 23, and 22 studies, respectively. 
 
Figure 1. Flowchart of studies included in meta-analysis.
3.2. Study Characteristics and Methodological Quality
The baseline characteristics of the included studies are presented in Table 1. Nine-
teen articles were retrospective co ort studies, and 10 were case series. Eight studies
included only patients with postoperative leaks, [13,23,25,26,33,42,43,46] and two studies
included only patients with perforations [24,27]. Eleven studies included patients with
both postoperative leaks and perforations [14,18,29,31,32,34,35,38,40,41,44]. Four studies
included patients with a fistula [36,37,45,47]. Four studies compared EVT with SEMS place-
ment [22,28,30,39]. A total of 24 studies were conducted in Western countries (Germany 14,
United States 4, Switzerland 2, United Kingdom 2, Portugal 1, and Australia 1), whereas
five studies were conducted in sia (Korea 4 and China 1).
The d finition of clinical su cess, detailed indi ations of treatment, and auses of
mortality in the includ d studies are shown in supplementary Table S2. In addition,
four s udies that included fistula cases are summarized in supplementary Table S3.
Th patient characteristics of studies comparing EVT and SEMS pl cement are sum-
marized in supplementary Table S4. Brangewitz et al. [22] reported successful closure,
mortality, duration of treatment, length of hospital stay, and stricture development in
71 patients with leaks or perforations after esophagectomies, fundoplications, esophageal
diverticulotomies, Boerhaave syndrome, and iatrogenic perforations, and compared EVT
(n = 32) with SEMS placement (n = 39). Schniewind et al. [23] assessed 47 patients diag-
nosed with postoperative leaks after esophagectomy. Mortality and length of hospital stay
were compared between patients treated with EVT (n = 17) and SEMS placement (n = 12).
Mennigen et al. [28] showed that successful closure, mortality, duration of treatment, length
of hospital stay, and adverse events were analysed in 45 patients who were diagnosed
with postoperative leak following esophagectomy in comparisons between EVT (n = 15)
versus SEMS (n = 30). Hwang et al. [30] compared EVT (n = 7) and SEMS placement
(n = 11) in South Korea. Although the number of enrolled patients was small, they also
showed successful closure, duration of treatment, length of hospital stay, and adverse
events. They included eighteen patients who were diagnosed with postoperative leak
after esophagectomy or gastrectomy for cancer treatment. Lastly, Berlth et al. [39] reported
successful closure, mortality, duration of treatment, length of hospital stay, and adverse
events in comparisons between EVT (n = 34) and SEMS (n = 77). One hundred and
eleven patients underwent curative surgery to treat malignancies and were diagnosed with
postoperative leaks.
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Table 1. Characteristics of 29 studies included.
























NA NA NA NA
Jung 2019 Retrospective Leak: 23Perforation: 7 20 65.1
† NA Western(Germany) 11.8
† NA NA Leak: 8.5Perforation: <1 NA IC: 6, IL: 24




NA 11 NA IC: 10, IL: 12
Watson 2019 Case series Leak: 2Fistula: 1 2 69.6
† NA Western (USA) 2.7 Endoscopy NA NA NA NA
Pinto 2019 Case series Leak: 2 1 44.0 † NA Western(Portugal) NA
Endoscopy
CT NA NA NA IC: 2, IL: 1
Morell 2019 Case series Leak: 6 2 49.0 † 44.2 Western(Switzerland) NA
Endoscopy
CT 20
† 4.5 † 3.3 † NA
Min 2019 Retrospective Leak: 20 20 66.5 NA Eastern(Korea) 7.1
Endoscopy
Esophagogram 17.5 12.5 3 IC: 20
Loske 2019 Case series Leak: 1Perforation: 10 4 65.7
† NA Western(Germany) NA
Endoscopy
CT NA NA NA IC: 1 IL: 10
Leeds 2019 Retrospective Leak: 54Perforation: 20 NA NA NA Western (USA) NA NA NA NA NA NA
Walsh 2019 Case series Leak: 1Perforation: 1 1 69.5 NA Western (USA) NA NA 20 21 NA NA
Alakkari 2019 Case series Leak: 1Perforation: 1 0 67













NA EVT: 8SEMS: 8
EVT: 0
SEMS: 0 NA

















NA NA NA IC: 3, IL: 7
Pournaras 2018 Retrospective Leak: 14Perforation: 7 NA NA NA Western (UK) NA NA NA NA NA NA
Ooi 2018 Retrospective Leak: 6Perforation: 4 NA 56.7
† NA Western(Australia) NA NA 18.3 NA 33.6 NA
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Table 1. Cont.




















Noh 2018 Retrospective Leak: 12 12 57.0 NA Eastern(Korea) 12.9
CT
Esophagogram 13 13.5 11 IC: 3, IL: 9
Loske 2018 Case series Leak: 3Perforation: 1 NA NA NA
Western










NA NA 8 NA















SEMS: 6.6 NA NA NA
Möschler 2015 Retrospective Leak: 5Perforation: 5 5 73.9













NA EVT: 7SEMS: 7 NA IC: 22
Loske 2015 Case series Perforation: 10 NA NA NA Western(Germany) 2.8 Endoscopy 19 <1 NA IC: 1, IL: 9




4.2 NA NA NA




NA 9.2 NA NA
Schorsch 2013 Retrospective Leak: 17 NA NA NA Western(Germany) NA NA 14.7 10 NA IC: 8, IL: 9
Schniewind
2013 Retrospective Leak: 47 NA NA NA
Western










(Germany) NA NA NA NA NA NA
EVT, endoscopic vacuum therapy; CT, computed tomography; IC, intracavitary; IL, intraluminary; NA, not available; SEMS, self-expanding metal stent † Data expressed as mean.
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Palmes 2020 Fistula: 4 2/4 (50) 2/4 (50) NA NA NA NA 88.5 NA
Jung 2019 Leak: 23 20/23 (87.0) 1/23 (4.3) 0/23 (0) 3/13 (23.1) 54.4 NA
15.7 3.4
Perforation: 7 5/7 (71.4) 1/7 (14.3) 0/7 (0) 1/2 (50.0) 33.7 27.0 6.4
Jeon 2019 Leak: 22 19/22 (86.4) 0/22 (0) 0/22 (0) 3/15 (20.0) 24 NA 13 3
Watson 2019
Leak: 2 2/2 (100.0) 0/2 (0) 0/2 (0) 0/2 (0)
NA NA
16 3
Fistula: 1 1/1 (100.0) 0/1 (0) 0/1 (0) 0/1 (0) 40 9
Pinto 2019 Leak: 2 1/2 (50.0) 0/2 (0) 0/2 (0) NA NA NA 22 3
Morell 2019 Leak: 6 6/6 (100.0) 0/6 (0) 0/6 (0) 0/6 (0) 39.8 † 10.2 † 32.3 † 4
Min 2019 Leak: 20 19/20 1/20 NA 6/19 49 NA 14.5 5
Loske 2019
Leak: 1 1/1 (100.0) 0/1 (0)
NA NA NA NA 11 1.8Perforation: 10 10/10 (100.0) 2/10 (20.0)
Leeds 2019
Leak: 54 44/54 (81.5)
NA NA NA NA NA NA NAPerforation: 20 19/20 (95.0)
Walsh 2019
Leak: 1 2/2 (100.0) 1/1 (100.0) 0/1 (0) NA NA NA
55 10
Perforation: 1 0/1 (0) 0/1 (0) 42 3
Alakkari 2019
Leak: 1 1/1 (100.0) 0/1 (0) 0/1 (0) 0/1 (0)
NA NA
28 6





24/34 (70.6) 3/34 (0.9) 0/27 (0) 1/27 (3.7) 37 8 12 3
49/77 (63.6) 11/77 (14.3) 13/69 (18.8) 5/69 (7.2) 38 7 27 1
Valli 2018
Leak: 11 9/11 (81.8) 0/11 (0) 0/11 (0) 2/11 (18.1)
NA NA
20.8 5
Fistula: 1 0/1 (0) 1/1 (100.0) 0/1 (0) 0/1 (0) 16 4
Still 2018
Leak: 2
NA 1/13 ‡ 1/13 ‡ NA NA NA NA NAPerforation: 9
Fistula: 2
Pournaras 2018
Leak: 14 14/14 (100.0) 0/14 (0) 1/14 (7.1)
NA 35 NA NA 7Perforation: 7 6/7 (85.7) 1/7 (14.3) 1/7 (14.3)
Ooi 2018
Leak: 6 4/6 (66.7) 1/6 (16.7) 2/6 (33.3)
NA 62 12 25.5 † 8.3 †Perforation: 4 2/4 (50.0) 1/4 (25.0) 1/4 (25.0)
Noh 2018 Leak: 12 10/12 (83.3) 1/12 (8.3) 1/12 (8.3) 1/12 (8.3) NA NA 25 2.7 †
Loske 2018
Leak: 3 3/3 (100.0) 0/3 (0) 0/3 (0) 0/3 (0)
NA NA NA NAPerforation: 1 1/1 (100.0) 0/1 (0) 0/1 (0) 0/1 (0)





















Leak: 39 36/39 (92.3) 5/39 (12.8) 2/39 (5.1) § 4/39 (10.2) 60
NA
20 6
Perforation: 13 13/13 (100.0) 0/13 (0) 0/13 (0) 0/13 (0) 46 24 6
Kuehn 2016

















7/11 (63.6) 6/11 (54.5) 87.3 19.2 1.6
Möschler 2015
Leak: 5 2/5 (40.0) 2/5 (40.0) 0/5 (0)
1/10 (10.0) § 38 NA
34.2 8.4










19/30 (63.3) 8/30 (26.6) 0/30 (0) 53 36 1
Loske 2015 Perforation: 10 10/10 (100.0) 0/10 (0) 0/10 (0) 0/10 (0) NA NA 5 2
Heits 2014 Perforation: 10 9/10 (90.0) 1/10 (10.0) NA NA 48 † 22 † NA 5.4 †
Liu 2014 Leak: 5 5/5 (100.0) 0/5 (0) 0/5 (0) NA NA NA 34.2 NA








57 † 26 †
NA NA
5/12 (41.7) 62 † 38 †
Brangewitz 2013 EVT:32 27/32 (84.4) 5/32 (15.6) 9/32 (28.1) 3/32 (9.4) 48.5 NA
23 7
SEMS: 39 21/39 (53.8) 11/39 (28.2) 3/39 (76.9) 11/39 (28.2) 41 33 3
EVT, endoscopic vacuum therapy; ICU, intensive care unit; NA, not available; SEMS, self-expanding metal stent † Data expressed as mean. ‡ Only total rate was available. § Two patients died because of fatal
hemorrhage during EVT.
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The methodological quality of the studies is presented in Supplementary Table S5.
The quality was poor in 15 studies [24,25,27,29,32,34,36–38,41–45,47] and moderate in
14 studies [13,14,18,22,23,26,28,30,31,33,35,39,40,46].
3.3. Primary and Secondary Outcomes
3.3.1. Primary Outcome—Successful Closure Rate
Twenty-seven studies reported data on successful closure in 456 patients. The pooled
estimate rate for successful closure was 0.85 (95% confidence interval [CI]: 0.81–0.88,
Figure 2). No heterogeneity was found among the studies (I2 = 0%, p = 0.68). No publication
bias was detected by the Egger test (p = 0.33).




Figure 2. Pooled estimate rate for successful closure in patients with transmural defects of upper gastrointestinal tract. 
3.3.2. Secondary Outcomes—Mortality, Complication, and Post-EVT Stricture Rates 
Data on mortality were reported in 28 studies comprising a total of 412 patients. The 
pooled estimated mortality rate was 0.11 (95% CI: 0.09–0.15, as illustrated in Figure 3A). 
No heterogeneity was found among these studies (I2 = 0%, p = 0.96). No publication bias 
was detected by the Egger test (p = 0.38). Twenty-one studies reported data on complica-
tions in 304 patients. The pooled estimate rate for complications was 0.10 (95% CI: 0.06–
0.15, as illustrated in Figure 3B). Low heterogeneity was found among the studies (I2 = 
13.8%, p = 0.28). Publication bias was detected by the Egger test (p < 0.05). Sixteen studies 
reported data on post-EVT strictures in 240 patients. The pooled estimate rate for post-
EVT stricture was 0.14 (95% CI: 0.10–0.20, as illustrated in Figure 3C). No heterogeneity 
was found among these studies (I2 = 0%, p = 0.45). The p-value of publication bias by the 
Egger test was 0.06. 
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bias was detected by the Egger test (p = 0.38). Twenty-one studies reported data on
complications in 304 patients. The pooled estimate rate for complications was 0.10 (95%
CI: 0.06–0.15, as illustrated in Figure 3B). Low heterogeneity was found among the studies
(I2 = 13.8%, p = 0.28). Publication bias was detected by the Egger test (p < 0.05). Sixteen
studies reported data on post-EVT strictures in 240 patients. The pooled estimate rate for
post-EVT stricture was 0.14 (95% CI: 0.10–0.20, as illustrated in Figure 3C). No heterogeneity
was found among these studies (I2 = 0%, p = 0.45). The p-value of publication bias by the
Egger test was 0.06.




Figure 3. (A) Pooled estimate rate for mortality in patients with transmural defects of upper gastrointestinal tract. (B) 
Pooled estimate rate for complications in patients with transmural defects of the upper gastrointestinal tract. (C) Pooled 
estimate rate for postendoscopic vacuum therapy stricture in patients with transmural defects of upper gastrointestinal 
tract. Abbreviations: No, number; OR, odds ratio; CI, confidence interval. 
3.4. Subgroup Analysis 
3.4.1. Perforation vs. Leak and Fistula—Successful Closure, Mortality, Complications, 
and Post-EVT Stricture Rates 
According to the etiology of the transmural defect, evaluation of the successful clo-
sure rate was performed in 11 studies. The pooled analysis showed that the successful 
closure rate was similar between the perforation and leak groups (odds ratio [OR]: 1.45, 
95% CI: 0.45–4.67, p = 0.53; as illustrated in Figure 4A). We detected low heterogeneity 
among the studies (I2 = 24.1%, p = 0.24). Data on mortality according to the etiology of 
transmural defects were available for 10 studies. The analysis revealed no significant dif-
ference between the two groups in terms of mortality rate (OR: 0.77, 95% CI: 0.24–2.46, p 
= 0.66; as illustrated in Figure 4B), and there was no heterogeneity (I2 = 0%, p = 0.58). Eight 
studies reported data on complications according to the etiology of transmural defects. 
The pooled analysis showed that the complication rates were similar between the perfo-
ration and leak groups (OR: 0.94, 95% CI: 0.17–5.15, p = 0.94; as illustrated in Figure 4C). 
No heterogeneity was detected among the studies (I2 = 0%, p = 0.79). Data on post-EVT 
stricture rate according to the etiology of transmural defects were available for five stud-
ies. No significant difference was observed between the two groups in terms of post-EVT 
stricture rate (OR: 0.70, 95% CI: 0.12–4.24, p = 0.70; as illustrated in Figure 4D), and no 
heterogeneity was noted (I2 = 0%, p = 0.47). 
Figure 3. (A) Pooled estimate rate for mortality in patients with transmural defects of upper gastrointestinal tract. (B) Pooled
estimate rate for complications in patients with transmural defects of the upper gastrointestinal tract. (C) Pooled estimate
rate for postendoscopic vacuum therapy stricture in patients with transmural defects of upper gastrointestinal tract.
Abbreviations: No, number; OR, odds ratio; CI, confidence interval.
3.4. Subgroup Analysis
3.4.1. Perforation vs. Leak and Fistula—Successful Closure, Mortality, Complications,
and Post-EVT Stricture Rates
According to the etiology of the transmural defect, evaluation of the successful closure
rate was performed in 11 studies. The pooled analysis showed that the successful closure
rate was similar between the perforation and leak groups (odds ratio [OR]: 1.45, 95% CI:
0.45–4.67, p = 0.53; as illustrated in Figure 4A). We detected low heterogeneity among the
studies (I2 = 24.1%, p = 0.24). Data on mortality according to the etiology of transmural
defects were available for 10 studies. The analysis revealed no significant difference
between the two groups in terms of mortality rate (OR: 0.77, 95% CI: 0.24–2.46, p = 0.66; as
illustrated in Figure 4B), and there was no heterogeneity (I2 = 0%, p = 0.58). Eight studies
reported data on complications according to the etiology of transmural defects. The pooled
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analysis showed that the complication rates were similar between the perforation and leak
groups (OR: 0.94, 95% CI: 0.17–5.15, p = 0.94; as illustrated in Figure 4C). No heterogeneity
was detected among the studies (I2 = 0%, p = 0.79). Data on post-EVT stricture rate
according to the etiology of transmural defects were available for five studies. No significant
difference was observed between the two groups in terms of post-EVT stricture rate
(OR: 0.70, 95% CI: 0.12–4.24, p = 0.70; as illustrated in Figure 4D), and no heterogeneity was
noted (I2 = 0%, p = 0.47).




Figure 4. (A) Forrest plot of successful closure rate for comparison between the perforation and leak group. (B) Forrest 
plot of mortality rate for comparison between perforation and leak groups. (C) Forrest plot of complication rate for com-
parison between perforation and leak groups. (D) Forrest plot of postendoscopic vacuum therapy stricture rate for com-
parison between perforation and leak groups. Abbreviations: No, number; OR, odds ratio; CI, confidence interval. 
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4. Discussion
To date, a st ies reported promising outcomes in patients with transmural
defects of the UGI tract with EVT used as a definitive treatment. However, th se previous
studies included only a li it f ti ts. Recently, several systematic reviews
reported the usefulnes of i l defects of the UGI tract. [19,48–50]; how ver,
these reviews wer only descriptive and i not conduct s atis cal n lysis with a sum ary
estimat . Ther fore, a meta-analysis is needed to compile and analyze the available d ta on
the efficacy of EVT in transmural defects of the UGI tract. Our meta-analysis included case
series in which a single group was assessed with no intrastudy comparisons. Nevertheless,
this me a-analysis has an dvantage over narra iv re iews because it assess d eff c sizes
and integrated them into a single statistical nalysis.
In this eta- t e closure rate of transmural UGI defects with EVT was ex-
cellent (85%), and EVT w associated with low mortality (11%), complications (10%),
and post-EVT stricture rates (14%) rates. Mor over, no significant difference wa observed
in successful closure (OR: 1.45, 95% CI: 0.45–4.67), mortality (OR: 0.77, 95% CI: 0.24–2.46),
complications (OR: 0.94, 95% CI: 0.17–5.15, p = 0.94), and post-EVT stricture rates (OR: 0.70,
95% CI: 0.12–4.24, p = 0.70) according to the etiology of the transmural defect ( erfora-
tion vs. leak and fistula). Although the etiology of trans ural UGI defects was different,
the efficacy of EVT was si ilar bet een the groups.
EVT had a significantly higher successful closure rate than with SEMS placement (OR:
3.14, 95% CI: 1.23–7.98). In addition, the mortality rate was lower (OR: 0.39, 95% CI: 0.18–0.83)
and the treatment duration was shorter with EVT than with SEMS placement (−11.90,
95% CI: −18.59–−5.21). We believe that this was due to the difference in methodology
between EVT and SEMS placement. Generally, SEMS removal or replacement is performed
4–6 weeks after SEMS insertion. Therefore, the successful closure rate with SEMS treatment
was determined 4–6 weeks after the previous SEMS insertion. In contrast, because EVT
is repeated every 3–5 days, clinicians can also check successful closure every 3–5 days.
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Therefore, successful closure could be detected sooner with EVT than with SEMS placement.
In addition, EVT treatment could offer the possibility of performing endoscopic lavage and
debridement with every change, which was shown to reduce pleural inflammation and
leakage-associated mortality.
The principle of EVT is similar to the classical vacuum-assisted closure treatment, which
is a well-established therapy for chronic superficial wounds [51]. In EVT, a polyurethane
sponge is placed inside the defect to apply negative pressure. Defect healing is achieved
through continuous abscess drainage, thus decreasing bacterial colonization, enhancing
vascularity, and promoting tissue granulation [51,52]. An internal vacuum sponge (endo-
SPONGE) device was first successfully used for treating a UGI anastomosis leak in 2008 [15].
Since then, EVT was used to manage UGI defects and showed good short- and long-term
clinical outcomes. SEMS placement also showed effective outcomes for UGI defects [7,8].
However, stent therapy is usually accompanied by additional abscess drainage, local
pressure necrosis of the mucosa, stent migration, stent ingrowth, bleeding, and perforation.
Surgery is also one of the strategies for treating transmural defects of the UGI; however,
it is associated with a high mortality rate [5,6]. To date, comparative studies assessing
different treatment modalities for UGI defects are rare [53]. Therefore, clinical evidence
of efficacy of EVT for treatment of UGI defects is still inadequate for directing treatment
modalities. Our meta-analysis showed that EVT is an effective and safe treatment method
for treating leaks, fistulae, and perforations.
Usually, transmural defects of the UGI tract are classified as perforations, leaks,
or fistulae. Of these, fistulae are the most difficult to close because the epithelial tract is often
fibrotic, and these arise in unhealthy tissues, which are inflamed, damaged, or ischemic.
Although the included cases were too few (n = 8), this meta-analysis showed a successful
closure rate of 50% in patients with a fistula. Given the inadequate response of fistulae to
other treatments such as SEMS placement, EVT is a promising option for treating patients
with fistula.
The major disadvantages of EVT are the need for repetitive endoscopic procedures,
nasogastric tube-related discomfort, and sponge dislocation. The main and most dreadful
event associated with EVT is massive bleeding [19,48]. It can occur from a fistula between
the cavity and main vessels and from rupture of a pseudoaneurysm from circumjacent
vessels or heart chambers. More frequent changes of the sponge may help prevent or reduce
the risk of severe bleeding. Moreover, massive bleeding can occur in cases of intracavitary
therapy in which direct contact with blood vessels is possible. Therefore, intraluminal EVT
may be safer than intracavitary EVT. Additionally, computed tomography scans should
be reviewed before initiating intracavitary EVT to exclude vascular complications. In our
review, post-EVT strictures occurred in 14% of cases; however, all strictures were easily
resolved through endoscopic dilatations (26 cases).
Although the results of this study are promising, it had several limitations. All in-
cluded studies were retrospective in nature without randomisation. This could have re-
sulted in a selection bias in this study. Typically, the choice of modalities (EVT, SEMS place-
ment, operation, and nonoperative management) were chosen according to the severity of
the patients. Patients managed conservatively tend not to be septic and have a contained
leak versus those who have apparent mediastinal contamination and warrant endoscopic
or surgical intervention. As EVT is a relatively new treatment method, it could be assumed
that the first experience of the studies included in this meta-analysis was performed in
cases in which a favorable outcome was expected, thus influencing the results. Although
randomized controlled trials are considered the best method for evaluating treatment
effects, performing such trials would be difficult owing to ethical concerns and method-
ological difficulties. Second, although the statistical heterogeneity was low, the clinical
heterogeneity was high among the included studies. Patient heterogeneity and detailed
indication were different among the included studies. Therefore, the complexity and co-
morbidities of each patient could affect the treatment success. In addition, SEMS placement
is a more standard treatment compared to EVT, which may also affect treatment outcomes.
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To address this limitation, we have additionally summarized detailed information of the
studies included in this meta-analysis (as illustrated in supplementary Tables S1–S4) Third,
the included studies had a limited quality. Fourth, the sample size of each study was
insufficient to reach definitive conclusions. Therefore, additional data are needed to define
the role of EVT in patients with UGI defects. Finally, most of the included studies were
from Western countries, especially Germany. Large-scale studies from other regions are
required to validate the usefulness of EVT in treating UGI defects in patients of different
ethnicities. Despite these limitations, to the best our knowledge, this meta-analysis contains
the most comprehensive analysis of the effectiveness of EVT for treating UGI defects.
5. Conclusions
In summary, this meta-analysis revealed that EVT could be an effective and safe
treatment method for leaks and fistulae as well as perforations in the UGI. In addition,
EVT may be a better treatment option than SEMS placement for UGI defects. However,
a definite recommendation cannot be made for the treatment of UGI defects due to the
limitations of the included studies mentioned above. We believe that prospective large-
scale studies from various regions worldwide are needed to validate the effectiveness of
EVT for treating UGI defects.
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